Skip to content

Tumor Necrosis Factor Alpha-Induced 3 (TNFAIP3) Protein, Mutation Analysis

Published: August 9, 2026Updated: August 16, 2026

This test checks for changes (mutations) in the TNFAIP3 gene, which may be linked to certain genetic conditions affecting immune function or cancer risk.

Quick summary

["Mutations in TNFAIP3 could influence how your body responds to inflammation or increase cancer risk—this test helps identify potential genetic variations."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
96968-3
Short code
TNFAIP3 Mut Anl Bld/T
Synonyms
TNFAIP3 Mut Anl Bld/T
Category
chemistry
Sample
whole-blood
Container
Lavender-top (EDTA)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
molgen
Specimen volume
3 mL
Stability
Room temperature: 4h, Refrigerated: 24h
Hemolysis max
0
Lipemia max
0
Icterus max
0
TAT
4–24 hours
Order
routine

Why This Test Might Be Ordered

Your healthcare provider may recommend this test if you have a family history of autoimmune diseases, inflammatory disorders, or certain cancers, or if genetic testing is part of a broader evaluation for suspected hereditary conditions.

What to Expect Before the Test

No special preparation is needed. You’ll provide a blood sample, which is typically drawn from a vein in your arm. If testing is part of a genetic panel, your provider will guide you through the process.

What the Results Mean

Results will indicate whether mutations in the TNFAIP3 gene are present. A positive finding may suggest an increased risk for conditions like autoimmune diseases or certain cancers, but additional testing or clinical correlation is often needed.

Common Conditions Linked to TNFAIP3 Mutations

While TNFAIP3 mutations are rare, they have been associated with conditions like inflammatory bowel disease, certain cancers (e.g., lymphoma), and autoimmune disorders. This test is not a routine screening but may be used in specific genetic evaluations.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

TNFAIP3 plays a role in regulating inflammation and cell survival. Mutations may disrupt normal immune responses, increasing susceptibility to chronic inflammation or cancer. Results help guide personalized medical management or surveillance strategies.

Short name

TNFAIP3 Gene Mutation Test

Frequently asked questions

Will this test show all possible mutations in TNFAIP3?
This test checks for specific known mutations in the TNFAIP3 gene. It may not detect all possible variations, so results should be interpreted by a healthcare provider familiar with genetic testing.
Can I stop taking medications before this test?
No special medication changes are required unless instructed by your provider. Some medications (e.g., blood thinners) may affect blood tests, but this test does not require discontinuation.
What if my results are positive for a TNFAIP3 mutation?
A positive result may raise concerns about an increased risk for autoimmune or inflammatory conditions or certain cancers. Your provider will discuss next steps, which may include additional genetic counseling or monitoring.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy